A New York federal judge is urging Eli Lilly to settle a multi-billion law suit filed by insurance companies and others who claim that the US drug major over charged for Zyprexa (olanzapine) and promoted it for off-label use.
US District Judge Jack Weinstein stated in a discussion draft that he is prepared to grant class action status to a law suit brought by Tennessee health insurance firm Mid-West National Life and other parties, urging the Indianapolis-headquartered drug major to settle the case, whose damages have been estimated to be between $3.9 billion and $7.7 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze